Patents by Inventor Elmar Wegener

Elmar Wegener has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers
    Patent number: 8575148
    Abstract: This invention concerns spiro azepane-ox-azolidinones as voltage gated Kv1.3 potassium channel blockers, pharmaceutical compositions containing these compounds, methods for preparing the compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in the treatment of diabetes, psoriasis, obesity, transplant rejection and inflammatory neuropathies, including T-cell mediated autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The compounds have formula (1): wherein R1, R2, (R3)n, and (R4)m have the meanings given in the specification.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: November 5, 2013
    Assignee: Abbott Healthcare Products B.V.
    Inventors: Pieter Smid, Michael Mlinaric, Konrad F. Koehler, Sara Nuñez Garcia, Elmar Wegener, Josephus H. M. Lange
  • SPIRO AZEPANE-OXAZOLIDINONES AS Kv1.3 POTASSIUM CHANNEL BLOCKERS
    Publication number: 20110237569
    Abstract: This invention concerns Spiro azepane-ox-azolidinones as voltage gated Kv1.3 potassium channel blockers, pharmaceutical compositions containing these compounds, methods for preparing the compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in the treatment of diabetes, psoriasis, obesity, transplant rejection and inflammatory neuropathies, including T-cell mediated autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The compounds have formula (1): wherein R1, R2, (R3)n, and (R4)m have the meanings given in the specification.
    Type: Application
    Filed: December 10, 2009
    Publication date: September 29, 2011
    Applicant: ABBOTT HEALTHCARE PRODUCTS B.V.
    Inventors: Pieter Smid, Michael Mlinaric, Konrad F. Koehler, Sara Nunez Garcia, Elmar Wegener, Josephus H.M. Lange